To evaluate whether α1-ECDmt treatment could confer significant benefit in the EAMG model over current mainstay treatments for patients with MG, we compared it to a cholinesterase inhibitor (pyridostigmine) and a corticosteroid (methylprednisolone) commonly used in clinical practice. The gene discussed is BCHE; the disease is myasthenia gravis.